Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to make medicines better, safer and easier to take, today announces that it has agreed a line extension in Brazil with its Brazilian partner Aché Pharmaceuticos (Aché) for a new version of its calcium and vitamin D chew marketed under the brand name Inellare.
Sales to Aché of this new format are expected to begin in Q3 2013.
Nigel Theobald, Chief Executive Officer of Oxford Pharmascience commented,
"Our chew business in Brazil continues to grow strongly and the addition of a new version of our calcium product in the Brazilian market shows both the commitment of our partner and the ongoing potential for the range."
For further information:
Oxford Pharmascience Group Plc
Nigel Theobald, Chief Executive +44 (0) 207 554 5875
Shaun Dobson/Jenny Wyllie +44 20 7496 3000
About Oxford Pharmascience Group Plc
Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.
Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.